VolitionRx price target raised to US$7 by microcap research house on high hopes for Nu.Q cancer screen – Proactive Investors UK

Proactive Investors UKVolitionRx Ltd (NYSEAMERICAN:VNRX), a Belgian company that develops easy-to-use blood-based tests to diagnose cancers, has considerable potential in the cancer-diagnostics market due to the accuracy of its tests and their low cost, according to a … and more …read more Source:: MicroCap Stock News From Google News

from WordPress http://ift.tt/2prwzud
via IFTTT

Newer Post Older Post